Additionally, the KEYNOTE-789 trial (NCT03515837) is another currently active Phase III trial evaluating pemetrexed-platinum combined with pembrolizumab versus placebo in EGFRm advanced NSCLC that has progressed on EGFR TKI (67). Here, EGFR is linked to non-small cell lung carcinoma.